WallStreetZenWallStreetZen

NASDAQ: NOVN
Novan Inc Stock

$1.20+0.03 (+2.56%)
Updated Mar 27, 2023
NOVN Price
$1.20
Fair Value Price
$1.78
Market Cap
$29.35M
52 Week Low
$0.79
52 Week High
$4.09
P/E
-0.65x
P/B
4.34x
P/S
3.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.86M
Earnings
-$36.52M
Gross Margin
69.3%
Operating Margin
-253.65%
Profit Margin
-263.6%
Debt to Equity
11.32
Operating Cash Flow
-$29M
Beta
0.93
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A

NOVN Overview

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NOVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NOVN ($1.20) is undervalued by 32.55% relative to our estimate of its Fair Value price of $1.78 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NOVN ($1.20) is significantly undervalued by 32.55% relative to our estimate of its Fair Value price of $1.78 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NOVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NOVN due diligence checks available for Premium users.

Be the first to know about important NOVN news, forecast changes, insider trades & much more!

NOVN News

Valuation

NOVN fair value

Fair Value of NOVN stock based on Discounted Cash Flow (DCF)
Price
$1.20
Fair Value
$1.78
Undervalued by
32.55%
NOVN ($1.20) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NOVN ($1.20) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NOVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NOVN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.65x
Industry
18.55x
Market
21.44x

NOVN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.34x
Industry
4.86x
NOVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NOVN's financial health

Profit margin

Revenue
$5.1M
Net Income
-$6.0M
Profit Margin
-117.9%
NOVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NOVN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$83.3M
Liabilities
$76.5M
Debt to equity
11.32
NOVN's short-term liabilities ($35.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NOVN's long-term liabilities ($40.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NOVN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NOVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.4M
Investing
-$3.0M
Financing
-$10.0M
NOVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NOVN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NOVN$29.35M+2.56%-0.65x4.34x
IMPL$29.45M-8.82%-0.27x-0.67x
ENTX$29.67M0.00%-0.69x2.07x
ERYP$29.78M+0.31%-0.89x1.33x
ABIO$29.81M-0.53%-3.00x0.72x

Novan Stock FAQ

What is Novan's quote symbol?

NASDAQ: NOVN) Novan trades on the NASDAQ under the ticker symbol NOVN. Novan stock quotes can also be displayed as NASDAQ: NOVN.

If you're new to stock investing, here's how to buy Novan stock.

What is the 52 week high and low for Novan (NASDAQ: NOVN)?

(NASDAQ: NOVN) Novan's 52-week high was $4.09, and its 52-week low was $0.79. It is currently -70.66% from its 52-week high and 51.9% from its 52-week low.

How much is Novan stock worth today?

(NASDAQ: NOVN) Novan currently has 24,462,228 outstanding shares. With Novan stock trading at $1.20 per share, the total value of Novan stock (market capitalization) is $29.35M.

Novan stock was originally listed at a price of $181.00 in Sep 21, 2016. If you had invested in Novan stock at $181.00, your return over the last 6 years would have been -99.34%, for an annualized return of -56.66% (not including any dividends or dividend reinvestments).

How much is Novan's stock price per share?

(NASDAQ: NOVN) Novan stock price per share is $1.20 today (as of Mar 27, 2023).

What is Novan's Market Cap?

(NASDAQ: NOVN) Novan's market cap is $29.35M, as of Mar 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Novan's market cap is calculated by multiplying NOVN's current stock price of $1.20 by NOVN's total outstanding shares of 24,462,228.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.